Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_47_библиотеки_им_акад_М_И_Перельмана
.pdf
152
30. Kusnierczyk P. Killer cell immunoglobulin-like receptor gene associations with autoim-
mune and allergic diseases, recurrent spontaneous abortion, and neoplasms. Front Immunol.
2013;4:8.
31. Karlsen TH, Boberg KM, Olsson M, Sun JY, Senitzer D, Bergquist A, etal. Particular genetic
variants of ligands for natural killer cell receptors may contribute to the HLA associated risk
of primary sclerosing cholangitis. J Hepatol. 2007 May;46(5):899–906.
32. Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson A, Lindgren S, etal.
Increased risk of primary sclerosing cholangitis and ulcerative colitis in rst-degree rela-
tives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2008
Aug;6(8):939–43.
33. Bowlus CL, Li CS, Karlsen TH, Lie BA, Selmi C.Primary sclerosing cholangitis in geneti-
cally diverse populations listed for liver transplantation: unique clinical and human leukocyte
antigen associations. Liver Transpl. 2010 Nov;16(11):1324–30.
34. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, etal. An iron delivery pathway mediated
by a lipocalin. Mol Cell. 2002 Nov;10(5):1045–56.
35. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, etal. Lipocalin 2 medi-
ates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004 Dec
16;432(7019):917–21.
36. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, etal. Dual action of
neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007 Feb;18(2):407–13.
37. Smith DF, Galkina E, Ley K, Huo Y.GRO family chemokines are specialized for monocyte
arrest from ow. Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H1976–84.
38. Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012 May
25;36(5):705–16.
39. Galli SJ, Grimbaldeston M, Tsai M.Immunomodulatory mast cells: negative, as well as posi-
tive, regulators of immunity. Nat Rev Immunol. 2008 Jun;8(6):478–86.
40. Pejler G, Ronnberg E, Waern I, Wernersson S.Mast cell proteases: multifaceted regulators of
inammatory disease. Blood. 2010 Jun 17;115(24):4981–90.
41. Matrisian LM.Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet.
1990 Apr;6(4):121–5.
42. Srivastava B, Mells GF, Cordell HJ, Muriithi A, Brown M, Ellinghaus E, etal. Fine mapping
and replication of genetic risk loci in primary sclerosing cholangitis. Scand J Gastroenterol.
2012 Jul;47(7):820–6.
43. Kuziel WA, Greene WC.Interleukin-2 and the IL-2 receptor: new insights into structure and
function. J Invest Dermatol. 1990 June;94(6 Suppl):27S–32S.
44. Melum E, Franke A, Schramm C, Weismuller TJ, Gotthardt DN, Offner FA, etal. Genome-
wide association analysis in primary sclerosing cholangitis identies two non-HLA suscepti-
bility loci. Nat Genet. 2011 Jan;43(1):17–9.
45. Han S, Stuart LA, Degen SJ.Characterization of the DNF15S2 locus on human chromosome
3: identication of a gene coding for four kringle domains with homology to hepatocyte
growth factor. Biochemistry. 1991 Oct 8;30(40):9768–80.
46. Yoshimura T, Yuhki N, Wang MH, Skeel A, Leonard EJ.Cloning, sequencing, and expression
of human macrophage stimulating protein (MSP, MST1) conrms MSP as a member of the
family of kringle proteins and locates the MSP gene on chromosome 3. J Biol Chem. 1993
July 25;268(21):15461–8.
47. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, et al.
PhosphoSitePlus: a comprehensive resource for investigating the structure and function of
experimentally determined post-translational modications in man and mouse. Nucleic Acids
Res. 2012 Jan;40(Database issue):D261–70.
48. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, etal. Interleukin
21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.
Nature. 2000 Nov 2;408(6808):57–63.
49. Cantrell DA, Smith KA.The interleukin-2 T-cell system: a new cell growth model. Science.
1984 Jun 22;224(4655):1312–6.
N. V. Bergasa
https://t.me/medicina_free
153
50. Folseraas T, Melum E, Rausch P, Juran BD, Ellinghaus E, Shiryaev A, etal. Extended analy-
sis of a genome-wide association study in primary sclerosing cholangitis detects multiple
novel risk loci. J Hepatol. 2012 Aug;57(2):366–75.
51. Bond J, Beynon R. The astacin family od metalloendopeptidases. Protein Sci.
1995;4(7):1247–61.
52. Marsters SA, Ayres TM, Skubatch M, Gray CL, Rothe M, Ashkenazi A.Herpesvirus entry
mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with mem-
bers of the TNFR-associated factor family and activates the transcription factors NF-kappaB
and AP-1. J Biol Chem. 1997 May 30;272(22):14029–32.
53. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a
hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986
Oct 10;47(1):19–28.
54. Ellinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T, etal. Genome-wide
association analysis in primary sclerosing cholangitis and ulcerative colitis identies risk loci
at GPR35 and TCF4. Hepatology. 2013 Sep;58:1074–83.
55. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, etal. Kynurenic acid as a ligand
for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006 Aug 4;281(31):22021–8.
56. Okumura S, Baba H, Kumada T, Nanmoku K, Nakajima H, Nakane Y, etal. Cloning of a
G-protein-coupled receptor that shows an activity to transform NIH3T3 cells and is expressed
in gastric cancer cells. Cancer Sci. 2004 Feb;95(2):131–5.
57. O’Dowd BF, Nguyen T, Marchese A, Cheng R, Lynch KR, Heng HH, etal. Discovery of
three novel G-protein-coupled receptor genes. Genomics. 1998 Jan 15;47(2):310–3.
58. D'Rozario M, Zhang T, Waddell EA, Zhang Y, Sahin C, Sharoni M, et al. Type I bHLH
Proteins Daughterless and Tcf4 Restrict Neurite Branching and Synapse Formation by
Repressing Neurexin in Postmitotic Neurons. Cell Rep. 2016;15(2):386–97.
59. Bain G, Murre C. The role of E-proteins in B- and T-lymphocyte development. Semin
Immunol. 1998 Apr;10(2):143–53.
60. Henthorn P, McCarrick-Walmsley R, Kadesch T.Sequence of the cDNA encoding ITF-2, a
positive-acting transcription factor. Nucleic Acids Res. 1990 Feb 11;18(3):678.
61. Bertin J, Guo Y, Wang L, Srinivasula SM, Jacobson MD, Poyet JL, etal. CARD9 is a novel
caspase recruitment domain-containing protein that interacts with BCL10/CLAP and acti-
vates NF-kappa B.J Biol Chem. 2000 Dec 29;275(52):41082–6.
62. Kelly RJ, Rouquier S, Giorgi D, Lennon GG, Lowe JB. Sequence and expression of a
candidate for the human secretor blood group alpha(1,2)fucosyltransferase gene (FUT2).
Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the
non-secretor phenotype. J Biol Chem. 1995 Mar 3;270(9):4640–9.
63. Wacklin P, Makivuokko H, Alakulppi N, Nikkila J, Tenkanen H, Rabina J, et al. Secretor
genotype (FUT2 gene) is strongly associated with the composition of Bidobacteria in the
human intestine. PLoS One. 2010;6(5):e20113.
64. Silva LM, Carvalho AS, Guillon P, Seixas S, Azevedo M, Almeida R, et al. Infection-
associated FUT2 (Fucosyltransferase 2) genetic variation and impact on functionality
assessed by invivo studies. Glycoconj J. 2010 Jan;27(1):61–8.
65. McGovern DP, Jones MR, Taylor KD, Marciante K, Yan X, Dubinsky M, et al.
Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum
Mol Genet. 2010 Sep 1;19(17):3468–76.
66. Juran BD, Atkinson EJ, Schlicht EM, Larson JJ, Ellinghaus D, Franke A, etal. Genetic poly-
morphisms of matrix metalloproteinase 3in primary sclerosing cholangitis. Liver Int. 2011
Jul;31(6):785–91.
67. Satsangi J, Chapman RW, Haldar N, Donaldson P, Mitchell S, Simmons J, etal. A functional
polymorphism of the stromelysin gene (MMP-3) inuences susceptibility to primary scleros-
ing cholangitis. Gastroenterology. 2001 July;121(1):124–30.
68. Wiencke K, Louka AS, Spurkland A, Vatn M, Schrumpf E, Boberg KM.Association of matrix
metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian pri-
mary sclerosing cholangitis patients. J Hepatol. 2004 Aug;41(2):209–14.
5
Primary Sclerosing Cholangitis
https://t.me/medicina_free
154
69. Wiesner RH, LaRusso NF, Ludwig J, Dickson ER.Comparison of the clinicopathologic fea-
tures of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology. 1985
Jan;88(1 Pt 1):108–14.
70. Bjornsson E, Simren M, Olsson R, Chapman RW.Fatigue in patients with primary sclerosing
cholangitis. Scand J Gastroenterol. 2004 Oct;39(10):961–8.
71. van Os E, van den Broek WW, Mulder PG, ter Borg PC, Bruijn JA, van Buuren HR.Depression
in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 2007
June;46(6):1099–103.
72. Benito de Valle M, Rahman M, Lindkvist B, Bjornsson E, Chapman R, Kalaitzakis E.Factors
that reduce health-related quality of life in patients with primary sclerosing cholangitis. Clin
Gastroenterol Hepatol. 2012 July;10(7):769–75.
73. Silveira MG, Mendes FD, Diehl NN, Enders FT, Lindor KD.Thyroid dysfunction in primary
biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver
Int. 2009 Aug;29(7):1094–100.
74. Lamberts LE, Janse M, Haagsma EB, van den Berg AP, Weersma RK. Immune-mediated
diseases in primary sclerosing cholangitis. Dig Liver Dis. 2011 Oct;43(10):802–6.
75. Venturini I, Cosenza R, Miglioli L, Borghi A, Bagni A, Gandolfo M, etal. Adult celiac dis-
ease and primary sclerosing cholangitis: two case reports. Hepato-Gastroenterology. 1998
Nov–Dec;45(24):2344–7.
76. Fracassetti O, Delvecchio G, Tambini R, Lorenzi N, Gavazzeni G.Primary sclerosing chol-
angitis with celiac sprue: two cases. J Clin Gastroenterol. 1996 Jan;22(1):71–2.
77. Man KM, Drejet A, Keeffe EB, Garcia-Kennedy R, Imperial JC, Esquivel CO.Primary scle-
rosing cholangitis and Hodgkin’s disease. Hepatology. 1993 Nov;18(5):1127–31.
78. Jonard P, Geubel A, Wallon J, Rahier J, Dive C, Meunier H.Primary sclerosing cholangitis
and idiopathic pulmonary brosis: a case report. Acta Clin Belg. 1989;44(1):24–30.
79. Fraile G, Rodriguez-Garcia JL, Moreno A.Primary sclerosing cholangitis associated with
systemic sclerosis. Postgrad Med J. 1991 Feb;67(784):189–92.
80. Abbas A, Lichtman A, Pillai S.Leukocytes migration into tissues. In: Abbas A, Lichtman A,
Pillai S, editors. Cellular and molecular immunology. Philadelphia: Elsevier; 2012.
81. Adams DH, Hubscher SG, Shaw J, Johnson GD, Babbs C, Rothlein R, et al. Increased
expression of intercellular adhesion molecule 1 on bile ducts in primary biliary cirrhosis and
primary sclerosing cholangitis. Hepatology. 1991 Sep;14(3):426–31.
82. Lindor KD, Wiesner RH, Katzmann JA, LaRusso NF, Beaver SJ.Lymphocyte subsets in
primary sclerosing cholangitis. Dig Dis Sci. 1987 Jul;32(7):720–5.
83. Cruickshank SM, Southgate J, Wyatt JI, Selby PJ, Trejdosiewicz LK.Expression of CD44 on
bile ducts in primary sclerosing cholangitis and primary biliary cirrhosis. J Clin Pathol. 1999
Oct;52(10):730–4.
84. Ponsioen CY, Kuiper H, Ten Kate FJ, van Milligen de Wit M, van Deventer SJ, Tytgat
GN.Immunohistochemical analysis of inammation in primary sclerosing cholangitis. Eur J
Gastroenterol Hepatol. 1999 Jul;11(7):769–74.
85. Ardesjo B, Portela-Gomes GM, Rorsman F, Grimelius L, Ekwall O.Identication of a novel
staining pattern of bile duct epithelial cells in primary sclerosing cholangitis. Inamm Bowel
Dis. 2010 Feb;16(2):305–11.
86. Hillan KJ, Hagler KE, MacSween RN, Ryan AM, Renz ME, Chiu HH, etal. Expression
of the mucosal vascular addressin, MAdCAM-1, in inammatory liver disease. Liver. 1999
Dec;19(6):509–18.
87. Grant AJ, Lalor PF, Hubscher SG, Briskin M, Adams DH.MAdCAM-1 expressed in chronic
inammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium
(MAdCAM-1in chronic inammatory liver disease). Hepatology. 2001 May;33(5):1065–72.
88. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH.Homing of mucosal lymphocytes to
the liver in the pathogenesis of hepatic complications of inammatory bowel disease. Lancet.
2002 Jan 12;359(9301):150–7.
N. V. Bergasa
https://t.me/medicina_free
155
89. Zaballos A, Gutierrez J, Varona R, Ardavin C, Marquez G. Cutting edge: identication of
the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK.J
Immunol. 1999 May 15;162(10):5671–5.
90. Zabel BA, Agace WW, Campbell JJ, Heath HM, Parent D, Roberts AI, etal. Human G protein-
coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal
homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-
expressed chemokine-mediated chemotaxis. J Exp Med. 1999 Nov 1;190(9):1241–56.
91. Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, etal. Lymphocyte
CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expres-
sion distinguish the small intestinal immune compartment: epithelial expression of tissue-
specic chemokines as an organizing principle in regional immunity. J Exp Med. 2000 Sep
4;192(5):761–8.
92. Kunkel EJ, Butcher EC. Chemokines and the tissue-specic migration of lymphocytes.
Immunity. 2002 Jan;16(1):1–4.
93. Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hubscher SG, etal. Hepatic endo-
thelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in
primary sclerosing cholangitis. J Exp Med. 2004 Dec 6;200(11):1511–7.
94. Liaskou E, Karikoski M, Reynolds GM, Lalor PF, Weston CJ, Pullen N, etal. Regulation of
mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhe-
sion protein 1 amine oxidase activity. Hepatology. 2011 Feb;53(2):661–72.
95. Harada K, Isse K, Nakanuma Y.Interferon gamma accelerates NF-kappaB activation of bili-
ary epithelial cells induced by toll-like receptor and ligand interaction. J Clin Pathol. 2006
Feb;59(2):184–90.
96. Mueller T, Beutler C, Pico AH, Shibolet O, Pratt DS, Pascher A, etal. Enhanced innate
immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial
cells contributes to chronic cholangitis. Liver Int. 2011 Nov;31(10):1574–88.
97. Gilmore TD.Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006
Oct 30;25(51):6680–4.
98. Gorgoulis VG, Pratsinis H, Zacharatos P, Demoliou C, Sigala F, Asimacopoulos PJ, etal.
p53-dependent ICAM-1 overexpression in senescent human cells identied in atherosclerotic
lesions. Lab Invest. 2005 Apr;85(4):502–11.
99. He L, Chen Y, Feng J, Sun W, Li S, Ou M, etal. Cellular senescence regulated by SWI/SNF
complex subunits through p53/p21 and p16/pRB pathway. Int J Biochem Cell Biol. 2017
Sep;90:29–37.
100. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, etal. Senescence-associated
secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53
tumor suppressor. PLoS Biol. 2008 Dec 2;6(12):2853–68.
101. Dorr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Dabritz JH, etal. Synthetic lethal metabolic
targeting of cellular senescence in cancer therapy. Nature. 2013 Sep 19;501(7467):421–5.
102. Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML, Hickman JJ.TEER measurement
techniques for invitro barrier model systems. J Lab Autom. 2015 Apr;20(2):107–26.
103. Tabibian JH, Trussoni CE, O’Hara SP, Splinter PL, Heimbach JK, LaRusso
NF.Characterization of cultured cholangiocytes isolated from livers of patients with primary
sclerosing cholangitis. Lab Invest. 2014 Oct;94(10):1126–33.
104. Tabibian JH, O’Hara SP, Splinter PL, Trussoni CE, LaRusso NF.Cholangiocyte senescence
by way of N-ras activation is a characteristic of primary sclerosing cholangitis. Hepatology.
2014 June;59(6):2263–75.
105. O’Hara SP, Splinter PL, Trussoni CE, Gajdos GB, Lineswala PN, LaRusso NF.Cholangiocyte
N-Ras protein mediates lipopolysaccharide-induced interleukin 6 secretion and proliferation.
J Biol Chem. 2011 Sep 2;286(35):30352–60.
106. Iebba V, Totino V, Gagliardi A, Santangelo F, Cacciotti F, Trancassini M, etal. Eubiosis and
dysbiosis: the two sides of the microbiota. New Microbiol. 2016 Jan;39(1):1–12.
5
Primary Sclerosing Cholangitis
https://t.me/medicina_free
156
107. Rogosa M, Bishop FS.The genus Veillonella. 3. Hydrogen sulde production by growing
cultures. J Bacteriol. 1964 July;88:37–41.
108. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, etal. Detection
of anaerobic bacteria in high numbers in sputum from patients with cystic brosis. Am J
Respir Crit Care Med. 2008 May 1;177(9):995–1001.
109. Nagel RA, Westaby D, Javaid A, Kavani J, Meire HB, Lombard MG, etal. Liver disease and
bile duct abnormalities in adults with cystic brosis. Lancet. 1989 Dec 16;2(8677):1422–5.
110. Elborn JS.Cystic brosis. Lancet. 2016 Nov 19;388(10059):2519–31.
111. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, etal. Lung microbiota
and bacterial abundance in patients with bronchiectasis when clinically stable and during
exacerbation. Am J Respir Crit Care Med. 2013 May 15;187(10):1118–26.
112. Lemoinne S, Kemgang A, Ben Belkacem K, Straube M, Jegou S, Corpechot C, etal. Fungi
participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis.
Gut. 2020 Jan;69(1):92–102.
113. Oztas E, Odemis B, Kekilli M, Kurt M, Dinc BM, Parlak E, etal. Systemic phaeohyphomy-
cosis resembling primary sclerosing cholangitis caused by Exophiala dermatitidis. J Med
Microbiol. 2009 Sep;58(Pt 9):1243–6.
114. Hong KH, Kim JW, Jang SJ, Yu E, Kim EC.Liver cirrhosis caused by Exophiala dermatitidis.
J Med Microbiol. 2009 May;58(Pt 5):674–7.
115. Nakanuma Y, Hirai N, Kono N, Ohta G.Histological and ultrastructural examination of the
intrahepatic biliary tree in primary sclerosing cholangitis. Liver. 1986 Dec;6(6):317–25.
116. Terasaki S, Nakanuma Y, Unoura M, Kaneko S, Kobayashi K. Involvement of peribili-
ary glands in primary sclerosing cholangitis: a histopathologic study. Intern Med. 1997
Nov;36(11):766–70.
117. Gaca MD, Pickering JA, Arthur MJ, Benyon RC.Human and rat hepatic stellate cells produce
stem cell factor: a possible mechanism for mast cell recruitment in liver brosis. J Hepatol.
1999 May;30(5):850–8.
118. Tsuneyama K, Kono N, Yamashiro M, Kouda W, Sabit A, Sasaki M, etal. Aberrant expres-
sion of stem cell factor on biliary epithelial cells and peribiliary inltration of c-kit- expressing
mast cells in hepatolithiasis and primary sclerosing cholangitis: a possible contribution to bile
duct brosis. J Pathol. 1999 Dec;189(4):609–14.
119. Kipp H, Arias IM.Trafcking of canalicular ABC transporters in hepatocytes. Annu Rev
Physiol. 2002;64:595–608.
120. Thoeni C, Waldherr R, Scheuerer J, Schmitteckert S, Roeth R, Niesler B, etal. Expression
analysis of ATP-binding cassette transporters ABCB11 and ABCB4 in primary Sclerosing
cholangitis and variety of pediatric and adult Cholestatic and Noncholestatic liver diseases.
Can J Gastroenterol Hepatol. 2019;2019:1085717.
121. Zen Y, Nakanuma Y, Portmann B.Immunoglobulin G4-related sclerosing cholangitis: patho-
logic features and histologic mimics. Semin Diagn Pathol. 2012 Nov;29(4):205–11.
122. Zhang L, Lewis JT, Abraham SC, Smyrk TC, Leung S, Chari ST, etal. IgG4+ plasma cell
inltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol. 2010
Jan;34(1):88–94.
123. Zen Y, Quaglia A, Portmann B. Immunoglobulin G4-positive plasma cell inltra-
tion in explanted livers for primary sclerosing cholangitis. Histopathology. 2011
Feb;58(3):414–22.
124. Boonstra K, Beuers U, Ponsioen CY.Epidemiology of primary sclerosing cholangitis and
primary biliary cirrhosis: a systematic review. J Hepatol. 2012 May;56(5):1181–8.
125. Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, et al. Incidence
of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011
May;53(5):1590–9.
126. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H.Incidence and prevalence
of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a
Norwegian population. Scand J Gastroenterol. 1998 Jan;33(1):99–103.
N. V. Bergasa
https://t.me/medicina_free
157
127. Lindkvist B, Benito de Valle M, Gullberg B, Bjornsson E. Incidence and prevalence of
primary sclerosing cholangitis in a dened adult population in Sweden. Hepatology. 2010
Aug;52(2):571–7.
128. Toy E, Balasubramanian S, Selmi C, Li CS, Bowlus CL. The prevalence, incidence and
natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC
Gastroenterol. 2011;11:83.
129. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, etal. Frequency and
risk factors for extraintestinal manifestations in the Swiss inammatory bowel disease cohort.
Am J Gastroenterol. 2011 Jan;106(1):110–9.
130. Lebovics E, Palmer M, Woo J, Schaffner F.Outcome of primary sclerosing cholangitis.
Analysis of long-term observation of 38 patients. Arch Intern Med. 1987 Apr;147(4):729–31.
131. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, etal. Natural history
and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut.
1996 Apr;38(4):610–5.
132. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, Rajaram R, Rauws EA, Mulder CJ, etal.
Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in
a Dutch population. Gut. 2002 Oct;51(4):562–6.
133. Floreani A, Zancan L, Melis A, Baragiotta A, Chiaramonte M.Primary sclerosing cholan-
gitis (PSC): clinical, laboratory and survival analysis in children and adults. Liver. 1999
June;19(3):228–33.
134. Garioud A, Seksik P, Chretien Y, Corphechot C, Poupon R, Poupon RE, etal. Characteristics
and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
Eur J Gastroenterol Hepatol. 2010 Jul;22(7):842–7.
135. Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, etal. Primary
sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology.
1989 Oct;10(4):430–6.
136. Helzberg JH, Petersen JM, Boyer JL.Improved survival with primary sclerosing cholangitis.
A review of clinicopathologic features and comparison of symptomatic and asymptomatic
patients. Gastroenterology. 1987 June;92(6):1869–75.
137. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN.Characterization, outcome, and
prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J
Gastroenterol. 2007 Jan;102(1):107–14.
138. Gossard AA, Angulo P, Lindor KD.Secondary sclerosing cholangitis: a comparison to pri-
mary sclerosing cholangitis. Am J Gastroenterol. 2005 June;100(6):1330–3.
139. Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M.Primary sclerosing cholangitis.
Lancet. 2018 June 23;391(10139):2547–59.
140. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, et al.
Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology.
1999 Apr;29(4):1050–6.
141. Henson JB, Patel YA, Wilder JM, Zheng J, Chow SC, King LY, etal. Differences in pheno-
types and liver transplantation outcomes by age group in patients with primary Sclerosing
cholangitis. Dig Dis Sci. 2017 Nov;62(11):3200–9.
142. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR.High lifetime risk of
cancer in primary sclerosing cholangitis. J Hepatol. 2009 Jan;50(1):158–64.
143. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD.Utility of serum tumor mark-
ers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing
cholangitis. Hepatology. 2008 Oct;48(4):1106–17.
144. Song J, Li Y, Bowlus CL, Yang G, Leung PSC, Gershwin ME. Cholangiocarcinoma in
patients with primary Sclerosing cholangitis (PSC): a comprehensive review. Clin Rev
Allergy Immunol. 2019 Aug;28:159–65.
145. Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, etal. Loss of tolerance to
gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in
primary sclerosing cholangitis. Sci Rep. 2018 Jan 10;8(1):399.
5
Primary Sclerosing Cholangitis
https://t.me/medicina_free
158
146. Jendrek ST, Gotthardt D, Nitzsche T, Widmann L, Korf T, Michaels MA, etal. Anti-GP2 IgA
autoantibodies are associated with poor survival and cholangiocarcinoma in primary scleros-
ing cholangitis. Gut. 2017 Jan;66(1):137–44.
147. Siqueira E, Schoen RE, Silverman W, Martin J, Rabinovitz M, Weissfeld JL, etal. Detecting
cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc.
2002 July;56(1):40–7.
148. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, etal. Cholangiocarcinoma
in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology.
2000 Jan;31(1):7–11.
149. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD.The value of serum CA 19-9in
predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci.
2005 Sep;50(9):1734–40.
150. Kipp BR, Barr Fritcher EG, Pettengill JE, Halling KC, Clayton AC.Improving the accuracy
of pancreatobiliary tract cytology with uorescence in situ hybridization: a molecular test
with proven clinical success. Cancer Cytopathol. 2013 Nov;121:610–9.
151. Kim DG, Park SY, You KR, Lee GB, Kim H, Moon WS, etal. Establishment and character-
ization of chromosomal aberrations in human cholangiocarcinoma cell lines by cross-species
color banding. Genes Chromosomes Cancer. 2001 Jan;30(1):48–56.
152. Langer-Safer PR, Levine M, Ward DC. Immunological method for mapping genes on
Drosophila polytene chromosomes. Proc Natl Acad Sci U S A. 1982 July;79(14):4381–5.
153. Barr Fritcher EG, Caudill JL, Blue JE, Djuric K, Feipel L, Maritim BK, etal. Identication of
malignant cytologic criteria in pancreatobiliary brushings with corresponding positive uo-
rescence in situ hybridization results. Am J Clin Pathol. 2011 Sep;136(3):442–9.
154. Kipp BR, Stadheim LM, Halling SA, Pochron NL, Harmsen S, Nagorney DM, etal. A com-
parison of routine cytology and uorescence in situ hybridization for the detection of malig-
nant bile duct strictures. Am J Gastroenterol. 2004 Sep;99(9):1675–81.
155. Barr Fritcher EG, Kipp BR, Voss JS, Clayton AC, Lindor KD, Halling KC, etal. Primary
sclerosing cholangitis patients with serial polysomy uorescence in situ hybridization results
are at increased risk of cholangiocarcinoma. Am J Gastroenterol. 2011 Nov;106(11):2023–8.
156. Osborn M, Weber K.Tumor diagnosis by intermediate lament typing: a novel tool for surgi-
cal pathology. Lab Invest. 1983 Apr;48(4):372–94.
157. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cyto-
keratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982
Nov;31(1):11–24.
158. Pujol JL, Grenier J, Parrat E, Lehmann M, Lafontaine T, Quantin X, etal. Cytokeratins as
serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS.Am J Respir Crit Care
Med. 1996 Sep;154(3 Pt 1):725–33.
159. Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K.Serum CYFRA 21-1 (cytokera-
tin- 19 fragments) is a useful tumour marker for detecting disease relapse and assessing treat-
ment efcacy in breast cancer. Br J Cancer. 2004 Aug 31;91(5):873–8.
160. Chapman MH, Sandanayake NS, Andreola F, Dhar DK, Webster GJ, Dooley JS, et al.
Circulating CYFRA 21-1 is a specic diagnostic and prognostic biomarker in biliary tract
Cancer. J Clin Exp Hepatol. 2011 Jun;1(1):6–12.
161. Giovannini M, Bories E, Monges G, Pesenti C, Caillol F, Delpero JR.Results of a phase I-II
study on intraductal confocal microscopy (IDCM) in patients with common bile duct (CBD)
stenosis. Surg Endosc. 2011 July;25(7):2247–53.
162. Lankisch TO, Metzger J, Negm AA, Vosskuhl K, Schiffer E, Siwy J, et al. Bile proteomic
proles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledo-
cholithiasis. Hepatology. 2011 Mar;53(3):875–84.
163. Metzger J, Negm AA, Plentz RR, Weismuller TJ, Wedemeyer J, Karlsen TH, etal. Urine
proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis
and other benign biliary disorders. Gut. 2013 Jan;62(1):122–30.
164. Tischendorf JJ, Kruger M, Trautwein C, Duckstein N, Schneider A, Manns MP, et al.
Cholangioscopic characterization of dominant bile duct stenoses in patients with primary
sclerosing cholangitis. Endoscopy. 2006 July;38(7):665–9.
N. V. Bergasa
https://t.me/medicina_free
159
165. Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK.Meta-analysis: ursodeoxycho-
lic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011 Oct;34(8):901–10.
166. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, etal. High-
dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology.
2009 Sep;50(3):808–14.
167. Lindstrom L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A. Association between
reduced levels of alkaline phosphatase and survival times of patients with primary Sclerosing
cholangitis. Clin Gastroenterol Hepatol. 2013 July;11:841–6.
168. Boner AL, Peroni D, Bodini A, Delaini G, Piacentini G. Azithromycin may reduce cho-
lestasis in primary sclerosing cholangitis: a case report and serendipitous observation. Int J
Immunopathol Pharmacol. 2007 Oct–Dec;20(4):847–9.
169. Farkkila M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, et al.
Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized
placebo-controlled trial. Hepatology. 2004 Dec;40(6):1379–86.
170. Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL.Long-term treatment of
primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating anti-
biotic. J Pediatr Gastroenterol Nutr. 2008 July;47(1):61–7.
171. Abarbanel DN, Seki SM, Davies Y, Marlen N, Benavides JA, Cox K, etal. Immunomodulatory
effect of vancomycin on Treg in pediatric inammatory bowel disease and primary sclerosing
cholangitis. J Clin Immunol. 2013 Feb;33(2):397–406.
172. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, etal. Randomised
clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis- a
pilot study. Aliment Pharmacol Ther. 2013 Mar;37(6):604–12.
173. Damman JL, Rodriguez EA, Ali AH, Buness CW, Cox KL, Carey EJ, etal. Review article:
the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis.
Aliment Pharmacol Ther. 2018 Apr;47(7):886–95.
174. Lammers WJ, van Buuren HR, Hirscheld GM, Janssen HL, Invernizzi P, Mason AL, etal.
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients
with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014
Dec;147(6):1338–49.e5.
175. Fickert P, Hirscheld GM, Denk G, Marschall HU, Altorjay I, Farkkila M, etal. norUrso-
deoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017
Sep;67(3):549–58.
176. Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, etal. The
nonsteroidal Farnesoid X receptor agonist Cilofexor (GS-9674) improves markers of cho-
lestasis and liver injury in patients with primary Sclerosing cholangitis. Hepatology. 2019
Sep;70(3):788–801.
177. Larusso NF, Levy C, Vuppalanchi R, Floreani A, Andreone P, Srestha R, Trotter J, Goldgerg
D, Rushbrook S, Hirscheld GM, Van Biene C, Penceck R, Macconell DS.The AESOP trial:
a randomized, double-blind, placebo-controlled, phase 2 study of obeticholic acid in patients
with primary sclerosing cholangitis. Dig Liver Dis. 2018;50(2):e67.
178. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, etal. A placebo-
controlled trial of Obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016 Aug
18;375(7):631–43.
179. Kowdley KV, Luketic V, Chapman R, Hirscheld GM, Poupon R, Schramm C, etal. A ran-
domized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.
Hepatology. 2018 May;67(5):1890–902.
180. Hirscheld GM, Chazouilleres O, Drenth JP, Thorburn D, Harrison SA, Landis CS, etal.
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, ran-
domized, double-blind, placebo-controlled phase II trial. J Hepatol. 2019 Mar;70(3):483–93.
181. Tabibian JH, Lindor KD. Ursodeoxycholic acid in primary sclerosing cholangitis: if with-
drawal is bad, then administration is good (right?). Hepatology. 2014 Sep;60(3):785–8.
182. Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, etal. Combination ther-
apy of all-trans retinoic acid with Ursodeoxycholic acid in patients with primary Sclerosing
cholangitis: a human pilot study. J Clin Gastroenterol. 2017 Feb;51(2):e11–e6.
5
Primary Sclerosing Cholangitis
https://t.me/medicina_free
160
183. Lemoinne S, Pares A, Reig A, Ben Belkacem K, Kemgang Fankem AD, Gaouar F, et al.
Primary sclerosing cholangitis response to the combination of brates with ursodeoxycholic
acid: French-Spanish experience. Clin Res Hepatol Gastroenterol. 2018 Dec;42(6):521–8.
184. Yu D, Cai SY, Mennone A, Vig P, Boyer JL. Cenicriviroc, a cytokine receptor antagonist,
potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents. Liver Int.
2018 June;38(6):1128–38.
185. Leban J, Kralik M, Mies J, Baumgartner R, Gassen M, Tasler S. Biphenyl-4-ylcarbamoyl
thiophene carboxylic acids as potent DHODH inhibitors. Bioorg Med Chem Lett. 2006 Jan
15;16(2):267–70.
186. Fitzpatrick LR, Deml L, Hofmann C, Small JS, Groeppel M, Hamm S, etal. 4SC-101, a
novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of
inammatory bowel disease. Inamm Bowel Dis. 2010 Oct;16(10):1763–77.
187. Trivedi PJ, Tickle J, Vesterhus MN, Eddowes PJ, Bruns T, Vainio J, etal. Vascular adhesion
protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and
facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner.
Gut. 2018 June;67(6):1135–45.
188. Arndtz K, Corrigan M, Rowe A, Kirkham A, Barton D, Fox RP, etal. Investigating the safety
and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary
sclerosing cholangitis (BUTEO): a single-arm, two-stage, open-label, multi-Centre, phase II
clinical trial protocol. BMJ Open. 2017 July 3;7(6):e015081.
189. Allegretti JR, Kassam Z, Carrellas M, Mullish BH, Marchesi JR, Pechlivanis A, etal. Fecal
microbiota transplantation in patients with primary Sclerosing cholangitis: a pilot clinical
trial. Am J Gastroenterol. 2019 July;114(7):1071–9.
190. Goldberg DS, Camp A, Martinez-Camacho A, Forman L, Fortune B, Reddy KR. Risk of
waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis.
Liver Transpl. 2013;19(3):250–8.
191. Aljiffry M, Renfrew PD, Walsh MJ, Laryea M, Molinari M.Analytical review of diagnosis
and treatment strategies for dominant bile duct strictures in patients with primary sclerosing
cholangitis. HPB. 2011 Feb;13(2):79–90.
192. Gotthardt DN, Rudolph G, Kloters-Plachky P, Kulaksiz H, Stiehl A.Endoscopic dilation
of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment.
Gastrointest Endosc. 2010 Mar;71(3):527–34.
193. Stiehl A, Rudolph G, Kloters-Plachky P, Sauer P, Walker S.Development of dominant bile
duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic
acid: outcome after endoscopic treatment. J Hepatol. 2002 Feb;36(2):151–6.
194. Kaya M, de Groen PC, Angulo P, Nagorney DM, Gunderson LL, Gores GJ, etal. Treatment
of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experi-
ence. Am J Gastroenterol. 2001 Apr;96(4):1164–9.
195. Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N.Impact of endoscopic therapy
on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc. 2001
Mar;53(3):308–12.
196. Rudolph G, Gotthardt D, Kloeters-Plachky P, Rost D, Kulaksiz H, Stiehl A. In PSC with
dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced
survival. J Hepatol. 2010 Aug;53(2):313–7.
197. Pausawasadi N, Soontornmanokul T, Rerknimitr R.Role of fully covered self-expandable
metal stent for treatment of benign biliary strictures and bile leaks. Korean J Radiol. 2012
Jan–Feb;13(Suppl 1):S67–73.
198. Eaton JE, Thackeray EW, Lindor KD.Likelihood of malignancy in gallbladder polyps and
outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol.
2012 Mar;107(3):431–9.
199. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, etal. Diagnosis
and management of primary sclerosing cholangitis. Hepatology. 2010 Feb;51(2):660–78.
200. Grossman EJ, Millis JM. Liver transplantation for non-hepatocellular carcinoma malig-
nancy: indications, limitations, and analysis of the current literature. Liver Transpl. 2010
Aug;16(8):930–42.
N. V. Bergasa
https://t.me/medicina_free
161
201. Wu Y, Johlin FC, Rayhill SC, Jensen CS, Xie J, Cohen MB, etal. Long-term, tumor-free sur-
vival after radiotherapy combining hepatectomy-Whipple en bloc and orthotopic liver trans-
plantation for early-stage hilar cholangiocarcinoma. Liver Transpl. 2008 Mar;14(3):279–86.
202. Friman S, Foss A, Isoniemi H, Olausson M, Hockerstedt K, Yamamoto S, etal. Liver trans-
plantation for cholangiocarcinoma: selection is essential for acceptable results. Scand J
Gastroenterol. 2011 Mar;46(3):370–5.
203. Gringeri E, Bassi D, D'Amico FE, Boetto R, Polacco M, Lodo E, etal. Neoadjuvant ther-
apy protocol and liver transplantation in combination with pancreatoduodenectomy for
the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing chol-
angitis: case report with a more than 8-year disease-free survival. Transplant Proc. 2011
May;43(4):1187–9.
204. Alvaro D, Cannizzaro R, Labianca R, Valvo F, Farinati F.Italian Society of G, et al. chol-
angiocarcinoma: a position paper by the Italian Society of Gastroenterology (SIGE), the
Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical
Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). Dig
Liver Dis. 2010 Dec;42(12):831–8.
205. Dasanu CA, Majumder S, Trikudanathan G.Emerging pharmacotherapeutic strategies for
cholangiocarcinoma. Expert Opin Pharmacother. 2011 Aug;12(12):1865–74.
206. Sia D, Tovar V, Moeini A, Llovet JM.Intrahepatic cholangiocarcinoma: pathogenesis and
rationale for molecular therapies. Oncogene. 2013 Jan;32:4861.
207. Brandsaeter B, Friman S, Broome U, Isoniemi H, Olausson M, Backman L, etal. Outcome
following liver transplantation for primary sclerosing cholangitis in the Nordic countries.
Scand J Gastroenterol. 2003 Nov;38(11):1176–83.
208. Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH.Evolving frequency and
outcomes of liver transplantation based on etiology of liver disease. Transplantation. 2013
Mar 15;95(5):755–60.
209. Florman S, Schiano T, Kim L, Maman D, Levay A, Gondolesi G, etal. The incidence and sig-
nicance of late acute cellular rejection (>1000 days) after liver transplantation. Clin Transpl.
2004 Apr;18(2):152–5.
210. Graziadei IW.Recurrence of primary sclerosing cholangitis after liver transplantation. Liver
Transpl. 2002 July;8(7):575–81.
211. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, etal. Long-
term results of patients undergoing liver transplantation for primary sclerosing cholangitis.
Hepatology. 1999 Nov;30(5):1121–7.
212. Moncrief KJ, Savu A, Ma MM, Bain VG, Wong WW, Tandon P. The natural history of
inammatory bowel disease and primary sclerosing cholangitis after liver transplantation: a
single-Centre experience. Can J Gastroenterol. 2010 Jan;24(1):40–6.
213. Graziadei IW.Live donor liver transplantation for primary sclerosing cholangitis: is disease
recurrence increased? Curr Opin Gastroenterol. 2011 May;27(3):301–5.
214. Fosby B, Karlsen TH, Melum E.Recurrence and rejection in liver transplantation for primary
sclerosing cholangitis. World J Gastroenterol WJG. 2012 Jan 7;18(1):1–15.
215. Davies YK, Tsay CJ, Caccamo DV, Cox KM, Castillo RO, Cox KL.Successful treatment of
recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral van-
comycin. Case Rep Transpl. 2013;2013:314292.
216. Joshi D, Bjarnason I, Belgaumkar A, O’Grady J, Suddle A, Heneghan MA, etal. The impact
of inammatory bowel disease post-liver transplantation for primary sclerosing cholangitis.
Liver Int. 2013 Jan;33(1):53–61.
217. Jorgensen KK, Lindstrom L, Cvancarova M, Castedal M, Friman S, Schrumpf E, et al.
Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver trans-
plantation: a Nordic multicenter study. Scand J Gastroenterol. 2012 Sep;47(8–9):1021–9.
218. Steenstraten IC, Sebib Korkmaz K, Trivedi PJ, Inderson A, van Hoek B, Rodriguez Girondo
MDM, etal. Systematic review with meta-analysis: risk factors for recurrent primary scleros-
ing cholangitis after liver transplantation. Aliment Pharmacol Ther. 2019 Mar;49(6):636–43.
219. Mieli-Vergani G, Vergani D.Unique features of primary sclerosing cholangitis in children.
Curr Opin Gastroenterol. 2010 May;26(3):265–8.
5 Primary Sclerosing Cholangitis
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана